Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (53)	4/27/1998 8:56:00 PM
From: Scott H. Davis	Respond to of 626

Positive Preliminary Results With Titan Pharmaceuticals' Spheramine in Primate Model of Parkinson's Disease Presented At American Society for Neural Transplantation Meeting. (link follows) Scott biz.yahoo.com

To: Arthur Radley who wrote (53)	4/27/1998 9:03:00 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 626

Texas Dude & All: a couple rookie TTNP questions. Could you expound on two things in the release, <utilized a well-established and validated rhesus monkey model of Parkinson's disease to evaluate Spheramine, which consists of therapeutic dopamine producing human cells attached to gelatin based microcarriers.> What is the "well established and validated rhesus monkey model"? I was not aware that monkeys developed Parkinson's, but I'm not a biologist either. And what is the source for "therapeutic dopamine producing human cells"? I don't think this could be a live donor program (unless it's from chinese prisoners or some other henious program), so is this cloning, a form of organ donation following accidental death or what? Curious, Scott